Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and residual risk
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have